BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
2 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 272] [Article Influence: 44.8] [Reference Citation Analysis]
3 Khalili K, Menezes R, Yazdi LK, Jang HJ, Kim TK, Sharma S, Feld J, Sherman M. Hepatocellular carcinoma in a large Canadian urban centre: stage at treatment and its potential determinants. Can J Gastroenterol Hepatol. 2014;28:150-154. [PMID: 24619637 DOI: 10.1155/2014/561732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:143-7. [PMID: 19207979 DOI: 10.1111/j.1478-3231.2008.01938.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
5 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
6 Tandon P, Low G, Mourtzakis M, Zenith L, Myers RP, Abraldes JG, Shaheen AA, Qamar H, Mansoor N, Carbonneau M, Ismond K, Mann S, Alaboudy A, Ma M. A Model to Identify Sarcopenia in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016;14:1473-1480.e3. [PMID: 27189915 DOI: 10.1016/j.cgh.2016.04.040] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 17.6] [Reference Citation Analysis]
7 Hasani FA, Knoepfli M, Gemperli A, Kollar A, Banz V, Kettenbach J, Jüni P, Dufour J. Factors affecting screening for hepatocellular carcinoma. Annals of Hepatology 2014;13:204-10. [DOI: 10.1016/s1665-2681(19)30883-x] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
8 Suh CH, Kim KW, Park SH, Shin S, Ahn J, Pyo J, Shinagare AB, Krajewski KM, Ramaiya NH. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. Eur Radiol. 2018;28:214-225. [PMID: 28726119 DOI: 10.1007/s00330-017-4967-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ryu MR, Kang ES, Park HD. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. J Clin Lab Anal 2019;33:e22921. [PMID: 31131509 DOI: 10.1002/jcla.22921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
11 Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-799. [PMID: 22374994 DOI: 10.1158/1055-9965.epi-11-1005] [Cited by in Crossref: 157] [Cited by in F6Publishing: 91] [Article Influence: 17.4] [Reference Citation Analysis]
12 Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35:232-239. [PMID: 24576055 DOI: 10.1111/liv.12516] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
13 Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HL, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology 2020;73:1368-78. [DOI: 10.1016/j.jhep.2020.07.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
14 Malik N, Venkatesh SK. Imaging of autoimmune hepatitis and overlap syndromes. Abdom Radiol (NY). 2017;42:19-27. [PMID: 27999888 DOI: 10.1007/s00261-016-1019-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
15 Mourad A, Deuffic-Burban S, Ganne-Carrié N, Renaut-Vantroys T, Rosa I, Bouvier AM, Launoy G, Cattan S, Louvet A, Dharancy S, Trinchet JC, Yazdanpanah Y, Mathurin P. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology 2014;59:1471-81. [PMID: 24677195 DOI: 10.1002/hep.26944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
16 Gomes NBN, Torres US, Ferraz MLCG, D'Ippolito G. Autoimmune hepatitis in practice, from diagnosis to complications: What is the role of imaging? A clinicoradiological review. Clin Imaging 2021;74:31-40. [PMID: 33429144 DOI: 10.1016/j.clinimag.2020.12.032] [Reference Citation Analysis]
17 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
18 Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987-1997. [PMID: 22144108 DOI: 10.1002/hep.24545] [Cited by in Crossref: 212] [Cited by in F6Publishing: 195] [Article Influence: 23.6] [Reference Citation Analysis]
19 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
20 Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh ND, Browning T, Singal AG. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. [PMID: 27862091 DOI: 10.1111/apt.13841] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 23.4] [Reference Citation Analysis]
21 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MAD, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology 2012;56:1089-96. [DOI: 10.1016/j.jhep.2011.11.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
23 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol 2021;75:108-19. [PMID: 33548385 DOI: 10.1016/j.jhep.2021.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
24 Lipp MJ, Broder A, Hudesman D, Suwandhi P, Okon SA, Horowitz M, Clain DJ, Friedmann P, Min AD. Detection of esophageal varices using CT and MRI. Dig Dis Sci. 2011;56:2696-2700. [PMID: 21380758 DOI: 10.1007/s10620-011-1660-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
25 Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 2020;30:2302-11. [DOI: 10.1007/s00330-019-06546-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
27 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
28 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
29 Hadorn D, Kvizhinadze G, Collinson L, Blakely T. Use of expert knowledge elicitation to estimate parameters in health economic decision models. Int J Technol Assess Health Care 2014;30:461-8. [PMID: 25682957 DOI: 10.1017/S0266462314000427] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
30 Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793-796. [PMID: 22689409 DOI: 10.1002/hep.25869] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 11.6] [Reference Citation Analysis]
31 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 972] [Article Influence: 188.2] [Reference Citation Analysis]
32 Chen JC, Wang LC, Kuo HT, Fang YC, Lee HF. Late-evening snacking improves liver functions in patients with liver cirrhosis: A meta-analysis of randomized controlled trials. J Gastroenterol and Hepatol. 2019;. [PMID: 30883904 DOI: 10.1111/jgh.14665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
33 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
34 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
35 Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 2011;13:783-91. [PMID: 21999591 DOI: 10.1111/j.1477-2574.2011.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
36 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
37 Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. J Clin Gastroenterol 2017;51:285-93. [PMID: 27661973 DOI: 10.1097/MCG.0000000000000671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
38 Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, Shechtel J, Chang Y, Loffredo C, Shetty K. The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. J Clin Gastroenterol. 2015;Epub ahead of print. [PMID: 25751372 DOI: 10.1097/mcg.0000000000000306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
39 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
40 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011;74:610-624.e2. [PMID: 21741639 DOI: 10.1016/j.gie.2011.05.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
43 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
44 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 90.0] [Reference Citation Analysis]
46 Khatri G, Pedrosa I, Ananthakrishnan L, Leon AD, Fetzer DT, Leyendecker J, Singal AG, Xi Y, Yopp A, Yokoo T. Abbreviated‐protocol screening MRI vs. complete‐protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI‐RADS v2018. J Magn Reson Imaging 2019;51:415-25. [DOI: 10.1002/jmri.26835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
47 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
49 K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. Dig Liver Dis 2015;47:296-302. [PMID: 25596930 DOI: 10.1016/j.dld.2014.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30. [PMID: 23333348 DOI: 10.1053/j.gastro.2013.01.021] [Cited by in Crossref: 125] [Cited by in F6Publishing: 121] [Article Influence: 15.6] [Reference Citation Analysis]
51 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
52 Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297. [PMID: 20483497 DOI: 10.1016/j.jhep.2010.03.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 16.7] [Reference Citation Analysis]
53 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Giannini EG, Trevisani F. Surveillance for hepatocellular carcinoma: just do it! Am J Gastroenterol. 2013;108:1013-1014. [PMID: 23735924 DOI: 10.1038/ajg.2013.98] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
55 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
56 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
57 Parikh ND. PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. Am J Gastroenterol 2017;112:1632-3. [PMID: 28972597 DOI: 10.1038/ajg.2017.366] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 14.0] [Reference Citation Analysis]
60 Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol. 2013;27:961-972. [PMID: 24182614 DOI: 10.1016/j.bpg.2013.08.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
61 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
62 Liu X, Xu J. Calling a stage-based treatment model for chronic liver diseases in China mainland. Ann Hepatol 2020;19:585-9. [PMID: 31711913 DOI: 10.1016/j.aohep.2019.09.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol 2012;6:441-4. [PMID: 22928896 DOI: 10.1586/egh.12.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
64 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
65 Chen Y, Lee J, Sridhar S(, Mittal V, Mccallister K, Singal AG. Improving Cancer Outreach Effectiveness Through Targeting and Economic Assessments: Insights from a Randomized Field Experiment. Journal of Marketing 2020;84:1-27. [DOI: 10.1177/0022242920913025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 12.0] [Reference Citation Analysis]
66 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
68 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3499] [Article Influence: 404.7] [Reference Citation Analysis]
69 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
70 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
71 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
72 Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017;66:1546-55. [DOI: 10.1002/hep.29315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
73 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1926] [Article Influence: 707.3] [Reference Citation Analysis]
74 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 163] [Article Influence: 33.4] [Reference Citation Analysis]
75 Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779-792. [PMID: 21357378 DOI: 10.1158/1055-9965] [Cited by in F6Publishing: 66] [Reference Citation Analysis]
76 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
77 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 656] [Article Influence: 165.3] [Reference Citation Analysis]
78 Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology. 2015;61:1056-1065. [PMID: 25041904 DOI: 10.1002/hep.27304] [Cited by in Crossref: 294] [Cited by in F6Publishing: 268] [Article Influence: 42.0] [Reference Citation Analysis]
79 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.Ann Hepatol. 2020;19:674-690. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
80 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
81 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 22.0] [Reference Citation Analysis]
82 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
83 Nam JY, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH. Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS One 2017;12:e0166188. [PMID: 28099520 DOI: 10.1371/journal.pone.0166188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
84 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-12. [PMID: 23750991 DOI: 10.1111/apt.12370] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
87 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int 2020;40:947-55. [PMID: 31943689 DOI: 10.1111/liv.14379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
89 Yoon JH, Park JW, Lee JM. Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean J Radiol 2016;17:7-24. [PMID: 26798212 DOI: 10.3348/kjr.2016.17.1.7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
90 Kim H, An J, Park J, Park S, Lim Y, Lee E. Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis. Hepatology 2019;69:1599-613. [DOI: 10.1002/hep.30330] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
91 Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. Am J Gastroenterol 2020;115:1642-9. [PMID: 32530829 DOI: 10.14309/ajg.0000000000000715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
92 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 96.0] [Reference Citation Analysis]
93 Boas FE, Do B, Louie JD, Kothary N, Hwang GL, Kuo WT, Hovsepian DM, Kantrowitz M, Sze DY. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015;26:69-73. [PMID: 25446423 DOI: 10.1016/j.jvir.2014.09.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
94 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 267] [Article Influence: 30.3] [Reference Citation Analysis]
95 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
96 Chung JW, Jang ES, Kim J, Jeong SH, Kim N, Lee DH, Lee KH, Kim JW. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2017;8:106499-510. [PMID: 29290966 DOI: 10.18632/oncotarget.22498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
97 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
98 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
99 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 49.0] [Reference Citation Analysis]
100 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
101 Han S, Choi JI, Park MY, Choi MH, Rha SE, Lee YJ. The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol 2018;19:568-77. [PMID: 29962863 DOI: 10.3348/kjr.2018.19.4.568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
102 Lima PH, Fan B, Bérubé J, Cerny M, Olivié D, Giard JM, Beauchemin C, Tang A. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:17-25. [PMID: 30995098 DOI: 10.2214/AJR.18.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
103 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
104 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Trinchet JC. Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life. J Hepatol 2011;54:1310-1. [PMID: 21296113 DOI: 10.1016/j.jhep.2010.11.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
106 Wong VW, Chan SL, Mo F, Chan T, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. JCO 2010;28:1660-5. [DOI: 10.1200/jco.2009.26.2675] [Cited by in Crossref: 290] [Cited by in F6Publishing: 106] [Article Influence: 26.4] [Reference Citation Analysis]
107 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
108 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 47.0] [Reference Citation Analysis]
109 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Reference Citation Analysis]
111 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
112 Szpakowski JL, Drasin TE, Lyon LL. Rate of seeding with biopsies and ablations of hepatocellular carcinoma: A retrospective cohort study. Hepatol Commun 2017;1:841-51. [PMID: 29404497 DOI: 10.1002/hep4.1089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
113 Sherman M. Modern Approach to Hepatocellular Carcinoma. Curr Gastroenterol Rep 2011;13:49-55. [DOI: 10.1007/s11894-010-0163-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
114 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
115 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
116 Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, Corvera CU, Yee J, Hope TA. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1627-33. [PMID: 29018942 DOI: 10.1007/s00261-017-1339-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
117 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
118 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 156.2] [Reference Citation Analysis]